403 related articles for article (PubMed ID: 29160844)
1. Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum.
Chen CM; Wu YR; Chang KH
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160844
[TBL] [Abstract][Full Text] [Related]
2. Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
Kao YH; Lin MS; Chen CM; Wu YR; Chen HM; Lai HL; Chern Y; Lin CJ
Hum Mol Genet; 2017 Feb; 26(3):467-478. PubMed ID: 28069792
[TBL] [Abstract][Full Text] [Related]
3. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
[TBL] [Abstract][Full Text] [Related]
4. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
5. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients.
Chang KH; Chen YC; Wu YR; Lee WF; Chen CM
PLoS One; 2012; 7(9):e46492. PubMed ID: 23029535
[TBL] [Abstract][Full Text] [Related]
7. Plasma inflammatory biomarkers for Huntington's disease patients and mouse model.
Chang KH; Wu YR; Chen YC; Chen CM
Brain Behav Immun; 2015 Feb; 44():121-7. PubMed ID: 25266150
[TBL] [Abstract][Full Text] [Related]
8. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.
Moffitt H; McPhail GD; Woodman B; Hobbs C; Bates GP
PLoS One; 2009 Nov; 4(11):e8025. PubMed ID: 19956633
[TBL] [Abstract][Full Text] [Related]
9. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.
Cowin RM; Roscic A; Bui N; Graham D; Paganetti P; Jankowsky JL; Weiss A; Paylor R
Behav Brain Res; 2012 Apr; 229(2):308-19. PubMed ID: 22306231
[TBL] [Abstract][Full Text] [Related]
10. Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.
Anglada-Huguet M; Giralt A; Rué L; Alberch J; Xifró X
Biochim Biophys Acta; 2016 Jul; 1862(7):1255-66. PubMed ID: 27063456
[TBL] [Abstract][Full Text] [Related]
11. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
12. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease.
Heng MY; Tallaksen-Greene SJ; Detloff PJ; Albin RL
J Neurosci; 2007 Aug; 27(34):8989-98. PubMed ID: 17715336
[TBL] [Abstract][Full Text] [Related]
14. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.
Woodman B; Butler R; Landles C; Lupton MK; Tse J; Hockly E; Moffitt H; Sathasivam K; Bates GP
Brain Res Bull; 2007 Apr; 72(2-3):83-97. PubMed ID: 17352931
[TBL] [Abstract][Full Text] [Related]
15. Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease.
Sebastianutto I; Cenci MA; Fieblinger T
Neurobiol Dis; 2017 Sep; 105():117-131. PubMed ID: 28578004
[TBL] [Abstract][Full Text] [Related]
16. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.
Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ
J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077
[TBL] [Abstract][Full Text] [Related]
17. Early Neurodegeneration in R6/2 Mice Carrying the Huntington's Disease Mutation with a Super-Expanded CAG Repeat, Despite Normal Lifespan.
Kielar C; Morton AJ
J Huntingtons Dis; 2018; 7(1):61-76. PubMed ID: 29480204
[TBL] [Abstract][Full Text] [Related]
18. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.
Saavedra A; García-Martínez JM; Xifró X; Giralt A; Torres-Peraza JF; Canals JM; Díaz-Hernández M; Lucas JJ; Alberch J; Pérez-Navarro E
Cell Death Differ; 2010 Feb; 17(2):324-35. PubMed ID: 19745829
[TBL] [Abstract][Full Text] [Related]
19. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
20. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]